Overcoming Challenges for Therapeutic Candidates
The white paper addresses the emerging challenges in data management and analysis software posed by the rise of chemically-modified, biologically-based therapeutic candidates in drug discovery, focusing on ensuring scientific rigor in candidate definition and automating data analysis workflows to support interdisciplinary research teams.
Overcoming Challenges for Therapeutic Candidates
The drug discovery research industry is experiencing a growing prevalence of chemically-modified, biologically-based therapeutic candidates. This trend introduces urgent and novel challenges for data management and analysis informatics software, which are essential for supporting cross-functional teams of scientists working across both biology and chemistry.
This white paper discusses key challenges and approaches to address them, including:
- Ensuring rigor in the scientific definition of candidate therapeutics
- Identifying opportunities to automate and streamline data analysis workflows
Related
Addressing Inefficient R&D Workflows
The blog discusses how legacy, fragmented R&D systems hinder innovation in complex, multi-domain scientific research by creating silos and inefficiencies, and presents Dotmatics’ unifying platform as a comprehensive solution that integrates diverse tools, data, and teams to enable smarter collaboration, governed data use, and AI-driven automation for faster, more rigorous innovation.
Reasonable Expectations, Clean Data, Collaboration: The Three Keys to AI in Drug Discovery
The article explains that while AI and machine learning have long been used in drug discovery, recent hype and massive investments have led to unrealistic expectations, emphasizing that success depends on setting reasonable goals, ensuring clean and abundant data, and fostering collaboration, as most AI-driven drug candidates remain in early development stages and face complex biological and practical challenges.
Our 11 Most-Read Blogs of 2023: AI, Biologics, ELNs, and More
Dotmatics' top blogs of 2023 highlight key scientific advancements including the convergence of small molecule and biologic drug development, the integration and comparison of LIMS and ELN systems for enhanced lab data management, and strategies to minimize human errors in biologics research through automation and calibration.
Don’t Get Distracted By AI, Instead Focus on Intellectual Property
Thomas Swalla, CEO of Dotmatics, argues in Pharmaceutical Executive that while AI accelerates drug development, pharmaceutical companies should prioritize intellectual property and robust data management as the essential foundations for true innovation and effective matching of drug candidates to diseases.
Data Evolution in Pharma: The Spread of Multimodal
The pharmaceutical industry is shifting from single-mode to multimodal drug discovery, incorporating diverse therapeutic modalities like biologics, gene therapies, and small molecules, but this evolution presents significant challenges in integrating heterogeneous R&D data and technologies, necessitating advanced, compatible platforms to enable efficient collaboration and leverage AI-driven insights for faster, cost-effective drug development.
Simplify your laboratory workflow management with Dotmatics
Dotmatics offers a unified scientific R&D platform that streamlines laboratory workflow management by integrating various scientific applications, automating data extraction, cleaning, and harmonization into FAIR formats, thereby reducing manual data handling, enhancing collaboration, and accelerating the R&D cycle to help life sciences organizations bring new therapies to market faster.